GET DAILY SIGNALSARS Pharmaceuticals (SPRY) Stock Slides -14% in 30 Days as Coverage Timeline Shifts
Key Takeaways
- SPRY shares have fallen about 14% over the trailing 30 days, sliding from roughly $4.13 to around $3.55.
- The decline extends a multi-month selloff that began after ARS disclosed in June that CVS Caremark's expanded coverage for neffy could be deferred from July 2026 to as late as January 2027.
- Over the most recent quarter, the stock is down roughly 37%, reflecting persistent uncertainty around payer coverage for the company's sole commercial product.
- Securities class action filings covering the period of March 9 to June 24, 2026, and a recent Form 144 filing by the chief commercial officer have added to negative sentiment.
- Management continues to emphasize neffy market-share gains, its chronic spontaneous urticaria program, and cost discipline aimed at a 2027 cash-breakeven target.
ARS Pharmaceuticals (SPRY) Company Overview and Market Position
ARS Pharmaceuticals is a San Diego-based biopharmaceutical company focused on treating severe allergic reactions. Its flagship product, SPRY, is a needle-free epinephrine nasal spray indicated in the United States for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and pediatric patients, and it is marketed as EURneffy in the European Union. Neffy is the first and only FDA- and European Commission-approved needle-free epinephrine product and the first new delivery method for epinephrine in more than 35 years.
The company competes against traditional auto-injectors such as the EpiPen and is also advancing neffy for chronic spontaneous urticaria (CSU), with a Phase 2b study underway. Investors follow the stock closely because commercial success depends heavily on expanding insurance coverage and removing prior-authorization barriers, which directly influence prescription volume for its only revenue-generating product. To compare sector peers, I also checked this using Tickeron’s AI Screener.
ARS Pharmaceuticals (SPRY) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, SPRY has declined approximately 14%, moving from a closing price near $4.13 in late September to roughly $3.55. The move has been characterized by steady downward pressure punctuated by elevated-volume sessions, rather than a single sharp catalyst during the period.
The quarterly picture is more pronounced. About three months ago, shares traded near $5.67, meaning the stock has lost roughly 37% over the quarter. This longer slide reflects a sustained repricing of the company's commercial outlook following the June coverage-timing disclosure, with the recent 30-day move representing a continuation of that broader trend.
What Drove SPRY Stock Price in the Last 30 Days
The 30-day decline was driven primarily by continued fallout from the company's June 24, 2026 announcement that CVS Caremark's expanded formulary coverage for neffy could be deferred from the previously guided July 1, 2026 effective date to as late as January 2027. That disclosure triggered a 23.9% single-session drop and reset investor expectations for near-term commercial acceleration.
During the most recent 30 days, a wave of securities class action announcements reinforced the negative backdrop. Multiple law firms publicized filings alleging the company misled investors about the timeline for CVS Caremark coverage, with a lead plaintiff deadline of October 5, 2026. Additionally, a Form 144 filed in mid-October indicated a proposed sale of securities by the chief commercial officer, which some investors read as a signal of insider sentiment. Together, these developments kept selling pressure on the shares despite management's messaging around steady neffy prescription growth.
What Drove SPRY Stock Performance Over the Last Quarter
The quarterly decline centers on payer-coverage risk. Neffy's commercialization relies on broad, low-friction insurance access, and the delay in expanded CVS Caremark coverage threatened prescriptions during the peak summer and back-to-school allergy seasons. With the coverage decision potentially pushed into early 2027, investors reduced their near-term revenue and market-share assumptions.
Broader factors compounded the slide. The company remains unprofitable, reporting a net loss in the second quarter despite roughly $33.7 million in revenue, and management has tied a 2027 cash-breakeven target to a January 2027 coverage approval. The securities litigation and insider-selling headlines further pressured a stock already trading well below its 52-week high. I ran a quick pattern check on this name with Tickeron’s AI Pattern Search Engine to see how similar situations played out historically.
SPRY Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor whether CVS Caremark finalizes expanded neffy coverage by January 2027, as the timing of payer access remains the single largest swing factor for prescription volume. Upcoming quarterly earnings and guidance updates will provide clarity on revenue trajectory, operating-expense discipline, and progress toward the company's cash-breakeven target. Interim data from the chronic spontaneous urticaria program, expected in the first quarter of the following year, represents a key pipeline catalyst that could expand the addressable market. Securities litigation developments, insider transaction filings, and broader biotech sector sentiment will also influence near-term trading.
Exploring Tickeron AI Tools for Market Analysis
In my own research workflow, I frequently turn to Tickeron’s AI Trading Bots to test automated strategies on names like this one. The platform offers hundreds of bots across thousands of tickers, with performance data and strategy details readily available. I find it helpful for identifying data-driven approaches when navigating volatile situations, especially when cross-checking signals from multiple timeframes. This kind of tool lets me stay objective without building everything from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRY's RSI Indicator recovers from oversold territory
The RSI Oscillator for SPRY moved out of oversold territory on September 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 27 of the 32 cases the stock moved higher. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +6.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 232 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for SPRY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.090) is normal, around the industry mean (3.070). P/E Ratio (-1.679) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement